The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine

Neuroscience

Volumn 164, Issue 2, 2009, Pages 667-675

  Fernandez Espejo, E ^a   Ramiro Fuentes, S ^a   Rodriguez de Fonseca, F ^b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

cocaine; morphine; neuroinflammation; PPAR; sensitization; WY14643

Indexed keywords

COCAINE; MORPHINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; PSYCHOSTIMULANT AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; FEMALE; GENOTYPE; HOMEOSTASIS; INFLAMMATION; MALE; MOTOR PERFORMANCE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; COCAINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHINE; MOTOR ACTIVITY; NARCOTICS; PPAR ALPHA; PYRIMIDINES; TIME FACTORS;

EID: 70349748796     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.08.023     Document Type: Article

References (47)

1. Akiyama T.E., Nicol C.J., Fievet C., Staels B., Ward J.M., Auwerx J., Lee S.S., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem 276 (2001) 39088-39093
2. Aoyama T., Peters J.M., Iritani N., Nakajima T., Furihata K., Hashimoto T., and Gonzalez F.J. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 273 (1998) 5678-5684
3. Beitner-Johnson D., and Nestler E.J. Morphine and cocaine exert common chronic actions on tyrosine hydroxylase in dopamine brain reward regions. J Neurochem 57 (1991) 344-347
4. Berhow M.T., Russell D.S., Terwilliger R.Z., Beitner-Johnson D., Self D.W., Lindsay R.M., and Nestler E.J. Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neuroscience 68 (1995) 969-979
5. Chang S.L., Kenigs V., Moldow R.L., and Zadina J.E. Chronic treatment with morphine and ethanol, but not cocaine, attenuates IL-1 beta activation of FOS expression in the rat hypothalamic paraventricular nucleus. Adv Exp Med Biol 373 (1995) 201-208
6. Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., and Marchand-LeRoux C. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR Alpha agonist, in traumatic brain injury. J Neurotrauma 24 7 (2007) 1119-1131
7. Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., and Kelly C.J. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol 169 12 (2002) 6806-6812
8. Cuzzocrea S., Mazzon E., Di P.R., Peli A., Bonato A., Britti D., Genovese T., Muià C., Crisafulli C., and Caputi A.P. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol 79 5 (2006) 999-1010
9. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPAR alpha-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
10. Delerive P., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169 (2001) 453-459
11. Diab A., Hussain R.Z., Lovett-Racke A.E., Chavis J.A., Drew P.D., and Racke M.K. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol 148 (2004) 116-126
12. Di Chiara G., and Imperato A. Drugs of abuse preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85 (1988) 5274-5278
13. Drew P.D., Xu J., Storer P.D., Chavis J.A., and Racke M.K. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int 49 2 (2006) 183-189
14. Fitzgerald L.W., Ortiz J., Hamedani A.G., and Nestler E.J. Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents. J Neurosci 16 (1996) 274-282
15. Galan-Rodriguez B., Suárez J., Gonzalez-Aparicio R., Bermudez-Silva F.J., Maldonado R., Robledo P., Rodriguez de Fonseca F., and Fernandez-Espejo E. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology 56 (2009) 653-664
16. House S.D., Mao X., Wu G., Espinelli D., Li W.X., and Chang S.L. Chronic morphine potentiates the inflammatory response by disrupting interleukin-1beta modulation of the hypothalamic-pituitary-adrenal axis. J Neuroimmunol 118 2 (2001) 277-285
17. Irwin M.R., Olmos L., Wang M., Valladares E.M., Motivala S.J., Fong T., Newton T., Butch A., Olmstead R., and Cole S.W. Cocaine dependence and acute cocaine induce decreases of monocyte proinflammatory cytokine expression across the diurnal period: autonomic mechanisms. J Pharmacol Exp Ther 320 2 (2006) 507-515
18. Jones S.W. Overview of voltage-dependent calcium channels. J Bioenerg Biomembr 30 (1998) 299-312
19. Kalivas P.W., and Duffy P. Repeated cocaine administration alters extracellular glutamate in the ventral tegmental area. J Neurochem 70 (1998) 1497-1502
20. Kelley A.E. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 44 (2004) 161-179
21. Koob G.F., and Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science 242 (1988) 715-723
22. Kubera M., Filip M., Basta-Kaim A., Nowak E., Siwanowicz J., Zajicova A., Holan V., Maes M., and Lason W. The effect of cocaine sensitization on mouse immunoreactivity. Eur J Pharmacol 483 (2004) 309-315
23. Licata S.C., and Pierce R.C. Calcium/calmodulin-dependent protein kinase II in the VTA contributes to cocaine-induced behavioral sensitization. Abstr Soc Neurosci 28 (2002) 289.6
24. Licata S.C., and Pierce R.C. The roles of calcium/calmodulin-dependent and Ras/mitogen-activated protein kinases in the development of psychostimulant-induced behavioral sensitization. J Neurochem 85 (2003) 14-22
25. Lleo A., Galea E., and Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 64 (2007) 1403-1418
26. Maeda T., Kiguchi N., Fukazawa Y., Yamamoto A., Ozaki M., and Kishioka S. Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice. Neuropsychopharmacology 32 5 (2007) 1133-1140
27. Marx N., Kehrle B., Kohlhammer K., Grüb M., Koenig W., Hombach V., Libby P., and Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90 6 (2002) 703-710
28. Melis M., Pillolla G., Luchicchi A., Montoni A.L., Yasar S., Goldberg S.R., and Pistis M. Endogenous fatty acid ethanolamides supress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 28 (2008) 13985-13994
29. Nakajima A., Yamada K., Nagai T., Uchiyama T., Miyamoto Y., Mamiya T., He J., Nitta A., Mizuno M., Tran M.H., Seto A., Yoshimura M., Kitaichi K., Hasegawa T., Saito K., Yamada Y., Seishima M., Sekikawa K., Kim H.C., and Nabeshima T. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci 24 9 (2004) 2212-2225
30. Narita M., Suzuki M., Kuzumaki N., Miyatake M., and Suzuki T. Implication of activated astrocytes in the development of drug dependence: differences between methamphetamine and morphine. Ann N Y Acad Sci 1141 (2008) 96-104
31. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2 (2001) 119-128
32. Nestler E.J. Is there a common molecular pathway for addiction?. Nat Neurosci 8 (2005) 1445-1449
33. Niwa M., Nitta A., Yamada K., and Nabeshima T. The roles of glial cell line-derived neurotrophic factor, tumor necrosis factor-alpha, and an inducer of these factors in drug dependence. J Pharmacol Sci 104 2 (2007) 116-121
34. Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., Noda Y., and Nabeshima T. Tumor necrosis factor-alpha and its inducer inhibit morphine-induced rewarding effects and sensitization. Biol Psychiatry 62 6 (2007) 658-668
35. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., and Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272 43 (1997) 27307-27312
36. Pierce R.C., Born B., Adams M., and Kalivas P.W. Repeated intra-ventral tegmental area administration of SKF-38393 induces behavioral and neurochemical sensitization to a subsequent cocaine challenge. J Pharmacol Exp Ther 278 (1996) 384-392
37. Racke M.K., Gocke A.R., Muir M., Diab A., Drew P.D., and Lovett-Racke A.E. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J Nutr 136 3 (2006) 700-703
38. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18 (1993) 247-291
39. Spanagel R., Almeida O.F.X., and Shippenburg T.S. Long-lasting changes in morphine-induced mesolimbic dopamine release after chronic morphine exposure. Synapse 14 (1993) 243-245
40. Schmidt A., Vogel R., Holloway M.K., Rutledge S.J., Friedman O., Yang Z., Rodan G.A., and Friedman E. Transcription control and neuronal differentiation by agents that activate the LXR nuclear receptor family. Mol Cell Endocrinol 155 (1999) 51-60
41. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 6687 (1998) 790-793
42. Stewart J., and Vezina P. Microinjections of SCH-23390 into the ventral tegmental area and substantia nigra pars reticulate attenuate the development of sensitization to the locomotor activating effects of systemic amphetamine. Brain Res 495 (1989) 401-406
43. Wise R.A. Addiction becomes a brain disease. Neuron 26 (2000) 27-33
44. Wise R.A., and Rompre P.P. Brain dopamine and reward. Annu Rev Psychol 40 (1989) 191-225
45. Xu J., Chavis J.A., Racke M.K., and Drew P.D. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 176 1-2 (2006) 95-105
46. Xu J., Racke M.K., and Drew P.D. Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J Neurochem 103 5 (2007) 1801-1810
47. Zalcman S., Savina I., and Wise R.A. Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats. Brain Res 847 2 (1999) 276-283